Today news
The same in other media
Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial
Reading now: 889
Apeiron Biologics has secured approvals from regulatory agencies in Austria, Germany and Denmark to conduct a Phase II clinical trial of APN01 for the treatment of Covid-19.
APN01 is the recombinant version of the human angiotensin-converting enzyme 2 (rhACE2) with a dual mechanism of action. The drug candidate imitates human ACE2 used by the virus to enter host cells, believed to possess the potential to inhibit Covid-19 infection and reduce lung injury.
Inhibition is thought to be possible as the virus attaches to soluble ACE2/APN01, rather than ACE2 on the cell surface, making the virus incapable of further infecting the cells.
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|